Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Diabetic macular edema (DME) is the accumulation of fluid in the macula due to leaking blood vessels resulting from diabetic retinopathy. Therapies targeting vascular endothelial growth factor (VEGF) have been shown to improve visual acuity in DME patients. The anti-VEGF agents used in the treatment of DME are Lucentis and Eylea—both approved for the treatment of DME—and off-label Avastin. In addition to the anti-VEGF therapies, two long-acting intravitreal corticosteroid implants, Ozurdex and Iluvien, were approved in the United States in 2014 for the treatment of DME. Given the competitive DME market, it is essential to understand how DME patients are currently being treated using real-world data.
What patient share do key therapies and brands garner by line of therapy in newly diagnosed DME patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DME patients?
How have intravitreal corticosteroid implants been integrated into the treatment algorithm?
What proportion of DME patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of DME patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with DME?
Brand/Therapy Usage Across Longitudinal Patient Sample
Newly Diagnosed Patient Analysis
Treatment Initiation and Progression Line of Therapy Analysis
Combination Therapy Analysis
Source of Business for Recently Treated Patients
Persistency and Compliance Analysis
Product-level Patient Flow Charts
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.
Diabetic Macular Edema / Diabetic Retinopathy - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
2019 Treatment Algorithms: Claims Data Analysis in Diabetic Macular Edema (January 2019)
Natalie Taylor, Ph.D.
Natalie Taylor, Ph.D., is a principal business insights analyst on the CNS/Ophthalmology Disorders team at Clarivate. She has more than ten years of experience authoring primary and market research reports for pharmaceutical industry clients in the fields of psychiatry, pain, neurology, and ophthalmology. Previously, Dr. Taylor worked at QuintilesIMS as manager of its CNS portfolio. She completed her Ph.D. in physiology at Dartmouth College in New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a B.S. in biology from Dickinson College in Pennsylvania.